Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2019-2030  

Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market size was valued at US$ 16.43 billion in 2023 and poised to reach US$ 18.3 billion by 2030 growing at a CAGR of 5.0% during the forecast period 2024 to 2030. Dipeptidyl Peptidase IV (DPP-IV) inhibitors also known as gliptins are oral anti-diabetic drugs, commonly used in the treatment of Type-2 diabetes. Dipeptidyl Peptidase inhibitors act by inhibiting the degradation of incretins like GLP-1 by inhibition of the enzyme dipeptidyl peptidase IV. The effect of incretin is prolonged, improving the glycemic control by various mechanisms, initially by stimulating the insulin synthesis and secretion in a glucose-dependent manner and by reduction of glucagon secretion. Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Market are commonly prescribed for the patients with type 2 diabetes especially who are not responded well to sulfonyl ureas and metformin. Dipeptidyl Peptidase IV inhibitors decrease blood glucose levels and help in weight loss. The common adverse effects associated with DPP IV inhibitors is Pancreatitis.

Increase in the prevalence and incidence of diabetic patients (According to the International Diabetes Federation, 7 million people are added every year to the pool of 246 million diabetics which increases to approximately 438 million by 2030. About 3.8 million People die each year from diabetes and even more, people die of other chronic diseases such as renal failure due to diabetes) expected to fuel the dipeptidyl peptidase IV inhibitors market. Geographically, dipeptidyl peptidase IV Inhibitors market is in booming stage in nature with several local and international players operating in the market. Launching of new products, approvals from various regulatory authorities such as U.S. Food and Drug Administration (U.S. FDA), acquisitions & mergers, and collaborations are some key strategies followed by various pharmaceutical companies for increasing their share in dipeptidyl peptidase IV inhibitors market.

Key Developments

• In March 2013, Otsuka obtains marketing approval in Japan for Onglyza tablets to treat Type 2 Diabetes. In April 2013, Takeda and Sanofi sign co-promotion agreement to expand the reach of diabetes treatment Alogliptin in China.
• In February 2014, AstraZeneca completed the acquisition of Bristol-Myers Squibb share of the global diabetic alliance.
• In May 2011, Boehringer Ingelheim GMBH, and Eli Lilly and Co. announced that the U.S. Food and Drug Administration (FDA) has approved Tradjen (linagliptin) tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
• In June 2011, the Tradjen was approved by European Medicines Agency (EMEA) in the Europe.